Shire’s drug picked up from Baxalta given fast track designation
March 23, 2017Research and Development, Sales and Marketing Shire, rare diseases
Shire has announced that its drug, SHP655, has received a fast track designation based on pre-clinical trials and positive results …
FDA approves first Parkinson’s treatment in a decade
March 22, 2017Research and Development, Sales and Marketing FDA, Parkinson's, Xadago
The FDA has approved Xadago (safinamide) as a supplementary treatment for Parkinson’s in patients currently taking levodopa/carbidopa and who are …
Alternative treatment cures rare blood disease for first time
March 22, 2017Research and Development congenital dyserythropoietic anaemia
A Chicago man has become the first person ever documented to be cured of congenital dyserythropoietic anaemia (CDA), a rare …
GSK begins £92 million expansion of UK site
March 22, 2017Manufacturing and Production, Research and Development GSK, UK
GSK has officially broken ground on the expansion of its site in County Durham. The expanded site will be an …
Novartis heart failure drug sinks at Phase 3 trials
March 22, 2017Research and Development Acute heart failure, Novartis, serelaxin
Novartis’ serelaxin was once thought to be the major hope for its cardiovascular pipeline – analysts projected it to become …
Novartis’ psoriasis drug allows some patients to go into remission
March 21, 2017Research and Development Cosentyx, Novartis, psoriasis
Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of …
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
Lilly’s breast cancer drug meets primary endpoint
March 21, 2017Manufacturing and Production, Research and Development CDK 4/6 inhibitors, Eli Lilly, abemaciclib
Eli Lilly has announced that its trial of abemaciclib, in combination with fulvestrant, had met its primary endpoint of progression-free …
India aims to become “a global innovation hub” for biotechs by 2020
March 21, 2017Manufacturing and Production, Research and Development India, biotech
The Indian Government has announced its intention to transform the nation into a hub for global biotech activity via its …
Biogaran acquires production foothold in Nigeria with Swipha acquisition
March 21, 2017Manufacturing and Production, Sales and Marketing Biogaran, Swipharma
Biogaran, the French generic manufacturer that is a subsidiary of Servier, has acquired a foothold in Nigeria with a 95% …
Array BioPharma in disarray over withdrawal of NDA
March 20, 2017Manufacturing and Production, Sales and Marketing Array Biopharma
Array BioPharma has announced that it has pulled its new drug application (NDA) for its drug, binimetinib, for the treatment …
Genentech plans second Phase 3 Alzheimer’s trial following endpoint failures
March 20, 2017Research and Development, Sales and Marketing Alzheimer's, Genentech, Roche
Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody …
China proposes ways to speed up approval for imported drugs
March 20, 2017Sales and Marketing China, imported drugs
It can currently take up to three or four years for a new drug to reach market in China, slowing …
Pakistan’s problem with diabetes – with 7 million diabetics
March 20, 2017Medical Communications, Sales and Marketing Pakistan, Sanofi, diabetes
Pakistan is facing an increasing problem with people suffering from diabetes. At a recent conference, the 4th International Diabetes Conference, …
UK biotech Pulmocide secures $30m for inhalable lung disease therapies
March 20, 2017Research and Development, Sales and Marketing pulmocide, pulmonary aspergillosis, respiratory syncytial virus
Pulmocide, a UK biotech run by a former GlaxoSmithKline scientists and based in London, has secured $30.4 million in Series …
Pregnancy test pill used through 60s & 70s connected with birth defects
March 20, 2017Medical Communications, Sales and Marketing Bayer, Primodos
A pregnancy test, named Primodos, which was taken by 1.5 million British mothers and was linked to birth defects, may …
Top Ten most popular articles on Pharmafile.com this week
March 17, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
As another week comes and goes, waves were sent through the industry as Trump announced his pick as the new …
Enhancing scientific acumen in the pharma boardroom
March 17, 2017Medical Communications R&D
Dana M. Krueger and Neha Rajdev, of Russell Reynolds, discuss the importance of a scientific background in the boardrooms of …
FDA warns API manufacturer about river water as ingredient
March 17, 2017Manufacturing and Production, Medical Communications Badrivishal Chemicals & Pharmaceuticals, FDA, India
The FDA has issued Badrivishal Chemicals & Pharmaceuticals a warning letter regarding numerous violations of manufacturing codes. The most worrying …
Ex-Novartis employee found not guilty of deceitful drug advertising
March 17, 2017Medical Communications, Sales and Marketing Diovan, Novartis, legal
A Tokyo court has ruled finding ex-Novartis employee Nobuo Shirahashi and the company’s Tokyo-based sales arm Novartis Pharma KK not …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
